Table 3 Crude incidence proportions for FN (broad definition) in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively, by receipt of pegfilgrastim prophylaxis*
| Â | Commercial | Medicare | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | FN in Cycle | Â | FN in Cycle | |||||
No. (%) in Each Category | No | Yes | Unadjusted OR (95% CI) | No. (%) in Each Category | No | Yes | Unadjusted OR (95% CI) | |
Cycle 1 | 50,778 | 48,157 (95%) | 2621 (5%) | Â | 71,037 | 64,249 (90%) | 6788 (10%) | Â |
 Use of Pegfilgrastim Prophylaxis | ||||||||
  No | 16,512 (33%) | 15,234 (92%) | 1278 (8%) | – | 20,195 (28%) | 17,901 (89%) | 2294 (11%) | – |
  Yes | 34,266 (67%) | 32,923 (96%) | 1343 (4%) | 2.1 (1.9–2.2) | 50,842 (72%) | 46,348 (91%) | 4494 (9%) | 1.3 (1.3–1.4) |
Cycle 2 | 41,769 | 40,810 (98%) | 959 (2%) | Â | 59,412 | 56,343 (95%) | 3069 (5%) | Â |
 Use of Pegfilgrastim Prophylaxis | ||||||||
  No | 11,719 (28%) | 11,353 (97%) | 366 (3%) | – | 15,193 (26%) | 14,282 (94%) | 911 (6%) | – |
  Yes | 30,050 (72%) | 29,457 (98%) | 593 (2%) | 1.6 (1.4–1.8) | 44,219 (74%) | 42,061 (95%) | 2158 (5%) | 1.2 (1.1–1.3) |
Cycles ≥3 | 98,075 | 96,006 (98%) | 2069 (2%) |  | 141,495 | 134,363 (95%) | 7132 (5%) |  |
 Use of Pegfilgrastim Prophylaxis | ||||||||
  No | 24,834 (25%) | 24,229 (98%) | 605 (2%) | – | 43,012 (30%) | 40,842 (95%) | 2170 (5%) | – |
  Yes | 73,241 (75%) | 71,777 (98%) | 1464 (2%) | 1.2 (1.1–1.3) | 98,483 (70%) | 93,521 (95%) | 4962 (5%) | 1.0 (1.0–1.1) |
Last Cycle | 34,860 | 33,426 (96%) | 1434 (4%) | Â | 51,989 | 45,392 (87%) | 6597 (13%) | Â |
 Use of Pegfilgrastim Prophylaxis | ||||||||
  No | 10,188 (29%) | 9705 (95%) | 483 (5%) | – | 20,099 (39%) | 17,851 (89%) | 2248 (11%) | – |
  Yes | 24,672 (71%) | 23,721 (96%) | 951 (4%) | 1.2 (1.1–1.4) | 31,890 (61%) | 27,541 (86%) | 4349 (14%) | 0.8 (0.8–0.8) |
All Cycles | 190,622 | 184,973 (97%) | 5649 (3%) | Â | 271,944 | 254,955 (94%) | 16,989 (6%) | Â |
 Use of Pegfilgrastim Prophylaxis | ||||||||
  No | 53,065 (28%) | 50,816 (96%) | 2249 (4%) | – | 78,400 (29%) | 73,025 (93%) | 5375 (7%) | – |
  Yes | 137,557 (72%) | 134,157 (98%) | 3400 (2%) | 1.7 (1.7–1.8) | 193,544 (71%) | 181,930 (94%) | 11,614 (6%) | 1.2 (1.1–1.2) |